TABLE 2.
Population characteristics of the patients in the propensity score-matched olanzapine cohort extracted from the JMDC data; quantifiable data are given as means ± SEM.
| With vitamin D | Without vitamin D | p-value | |
|---|---|---|---|
| Patients | 20 | 20 | NA |
| Elderly (≥65) | 1 (5.0%) | 1 (5.0%) | 1 |
| Female | 18 (90.0%) | 18 (90.0%) | 1 |
| Schizophrenia | 4 (20.0%) | 7 (35.0%) | 0.48 |
| Antipsychotics | 6 (30.0%) | 9 (45.0%) | 0.51 |
| Blood glucose (mg/dL) | 91.9 ± 2.3 | 92.2 ± 3.1 | 0.94 |
| HbA1c (%) (mg/dL) | 5.49 ± 0.07 | 5.49 ± 0.12 | 0.97 |
| Triglyceride (mg/dL) | 97.6 ± 9.6 | 77.4 ± 12.0 | 0.2 |
| LDL cholesterol (mg/dL) | 120.7 ± 6.2 | 117.5 ± 5.1 | 0.69 |
| HDL cholesterol (mg/dL) | 68.1 ± 3.7 | 72.2 ± 3.4 | 0.42 |
| BMI | 20.3 ± 1.0 | 19.3 ± 0.6 | 0.38 |
| Waist circumference (cm) | 75.1 ± 2.5 | 71.2 ± 1.5 | 0.19 |